Cell-surface receptors guide antisense therapy to mutant KRAS in pancreatic cancer cells. Antisense oligonucleotides (ASOs) have been proposed as a therapeutic approach to shut down the production of faulty proteins in a wide variety of diseases, including cancer.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Antisense oligonucleotides (ASOs) have been proposed as a therapeutic approach to shut down the production of faulty proteins in a wide variety of diseases, including cancer. In a study published in the Journal of Cell Biology (JCB), researchers at the Cancer Research UK Scotland Institute and the University of Glasgow identify a pathway by which ASOs enter cells and reach their targets, suggesting new ways to enhance the effectiveness of antisense therapy.
- Ponto de atenção: cell.
- Ponto de atenção: surface.
- Ponto de atenção: receptors.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
